Study Details

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03118713

Astellas Study ID

The unique identification code given by the study sponsor.

1941-MA-3122-KR

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Adult Onset Diabetes

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

19 years - 74 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2017 - Dec 2018

Masking

None (Open Label)

Enrollment number

33

A Phase 4, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Renal Protective Effect (UACR), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site 02

Deagu, Republic of Korea

Site 07

Seoul, Republic of Korea

Site 10

Seoul, Republic of Korea

Site 06

Daejeon, Republic of Korea

Site 15

Bucheon-si, Republic of Korea

Site 12

Suwon-si, Republic of Korea

Site 17

Seoul, Republic of Korea

Site 04

Bucheon-si, Gyueonggi-do, Republic of Korea

Site 11

Guri-si, Republic of Korea

Site 05

Seoul, Republic of Korea

Site 03

Goyang-si, Gyueonggi-do, Republic of Korea

Site 09

Seoul, Republic of Korea

Site 18

Seoul, Republic of Korea

Site 13

Busan, Republic of Korea

Site 08

Gwangju, Republic of Korea

Site 14

Seoul, Republic of Korea

Site 01

Seoul, Republic of Korea